Global Streptokinase Market Overview:
Streptokinase is referring as a sterile, which is a purified preparation of a protein consists of bacteria, elaborated by group C (beta) that is hemolytic streptococci. Streptokinase is supplied as a lyophilized white powder which contains 25 mg cross-linked gelatin polypeptides, sodium hydroxide to adjust pH, 25 mg sodium L-glutamate and 100 mg Albumin (Human) per vial or infusion bottle as stabilizers. The preparation of it contains no preservatives and it is intended for intracoronary and intravenous administration. Streptokinase is normally used to dissolve blood clots which have been formed in the blood vessels. It is immediately used after the symptoms of a heart attack occur to improve the patient survival. This medicine can also be used to treat the blood clots in the legs and the lungs.
- Increasing geriatric population
- Rising awareness related to personal healthcare
- Growing camps associated with the health knowledge
- Side effects associated with the intake of serratiopeptidase
- Growth potential offered by emerging countries
- The high cost associated with the products
The market is fragmented by key vendors who are focusing on production technologies, improving efficiency and shelf life. Growth opportunities can be captured by tracking the ongoing process improvement and financial flexibility to invest in optimal strategies
Some of the key players profiled in the report are SAMARTH PHARMA (India), Biocon (India), Kee Pharma (India), Dabur (India), Biosena (India), Wanbang Biopharma (China), Qingdao GD Biotechnology Pharmaceutical (China), Aristo Pharmaceuticals (India), Neiss Labs (India) and Ahaan Healthcare Pvt Ltd. (AHPL) (India). Additionally, following companies can also be profiled that are part of our coverage like TTK HealthCare (India), Incepta pharmaceuticals limited (Bangladesh) and Cadila (India). Considering Market by Way of ordering, the sub-segment i.e. Walk-in will boost the Streptokinase market.
Sirona Biochem Corp. announced that partner Jiangsu Wanbang Biopharmaceuticals has confirmed an Investigational New Drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor. The application will be reviewed by the CFDA for acceptance into clinical trials
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Streptokinase market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Streptokinase market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Streptokinase Manufacturers, Streptokinase Distributors/Traders/Wholesalers, Streptokinase Subcomponent Manufacturers, Industry Association and Downstream Vendors.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.